US Stock MarketDetailed Quotes
BLCM Bellicum Pharmaceuticals
Watchlist
0.201
+0.001+0.40% Close 12/08 16:00 ET
0.249High0.200Low11.82KVolume
0.200Open0.200Pre Close2.57KTurnover0.14%Turnover RatioLossP/E (TTM)1.95MMarket Cap1.50052wk HighLossP/E (Static)9.72MShares0.06052wk Low-0.07P/B1.74MFloat Cap336.300Historical High--Dividend TTM8.64MShs Float0.060Historical Low--Div YieldTTM24.55%Amplitude0.217Avg Price1Lot Size
About Bellicum Pharmaceuticals Company
Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX.
Company Profile
SymbolBLCM
Company NameBellicum Pharmaceuticals
Listing Date12/18/2014
Issue Price19.00
Founded2004
CEOMr. Richard A. Fair
MarketPink Market
Employees13
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address3730 Kirby Drive,Suite 1200
CityHouston
ProvinceTexas
CountryUnited States of America
Zip Code77098
Phone1-281-454-3424
Websitehttp://www.bellicum.com
Company Executives
- Name
- Position
- Salary
- Richard A. Fair
- President, Chief Executive Officer, Principal Financial Officer and Director
- 1.47M
- Dr. Charity Scripture
- Chief Development Officer
- 513.99K
- Charles S. Grass
- Principal Accounting Officer
- --
- Jon P. Stonehouse
- Chairman of the Board
- 102.73K
- Stephen R. Davis
- Independent Director
- 92.90K
- James M. Daly
- Independent Director
- 73.97K
- Dr. Reid M. Huber, PhD
- Independent Director
- 96.18K
- Dr. Judith Klimovsky
- Independent Director
- 75.13K